Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-br- -ergocryptine (CB 154), an inhibitor of prolactin secretion, and by nafoxidine (U-11, 100 A), an estrogen antagonist.
D000818:Animals; D001551:Benz(a)Anthracenes; D001966:Bromine / Q000494:pharmacology; D002471:Cell Transformation, Neoplastic; D004876:Ergot Alkaloids / Q000494:pharmacology*; D004965:Estrogen Antagonists; D004971:Estrus; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced* / Q000188:drug therapy; D009281:Naphthalenes / Q000494:pharmacology; D010053:Ovary / Q000502:physiology; D010636:Phenols / Q000494:pharmacology*; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors
D001551:Benz(a)Anthracenes; D004876:Ergot Alkaloids; D004965:Estrogen Antagonists; D009281:Naphthalenes; D010636:Phenols; D011759:Pyrrolidines; D011388:Prolactin; D001966:Bromine